PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization
29 Nov 2022
VaccinePhase 2Immunotherapy
Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study compares PharmaJet’s Tropis intradermal, needle-free injection system against traditional needle and syringe intramuscular administration.
According to a news release, the study will be performed in collaboration with Padjadjaran University (UNPAD) in Indonesia. PharmaJet expects the study to recruit approximately 900 girls aged nine to 14 years old in early 2023. This follows PharmaJet’s preliminary studies evaluating intradermal delivery for HPV vaccines.
Get the full story at our sister site, Drug Delivery Business News.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.